
In a finding that suggests Ozempic and Wegovy have powers that extend beyond weight loss, a new study finds the medications might also lower people’s risk of opioid overdose. People with type 2 diabetes prescribed semaglutide (Ozempic, Wegovy) had a significantly lower risk of an opioid OD than patients taking any of eight other diabetic medications, researchers found. The results show “semaglutide as a possible new treatment for combating this terrible [opioid] epidemic,” said lead researcher Rong Xu, a biomedical informatics professor at Case Western Reserve University in Cleveland. For the study, researchers analyzed six years of medical data for nearly 33,000 patients with opioid use disorder who also had type 2 diabetes. The data found that those prescribed semaglutide were less likely to suffer from an opioid overdose. The new study was published Sept. 25 in the journal JAMA Network Open. If this effect is confirmed in clinical trials, semaglutide could provide a new means of protecting people suffering from opioid addiction, Xu said in a university news release. About 107,500 people died from drug ODs in 2023 in the United States, mainly from opioids, researchers said in background notes. About 72% of drug ODs involve opioids. Only about a quarter of people with opioid addiction are taking effective medicines to prevent overdoses, and half discontinue treatment within six months, researchers said. “Not everyone… read on > read on >